Development of PET Radioisotope Copper-64-Labeled Theranostic Immunoliposomes for EGFR Overexpressing Cancer-Targeted Therapy and Imaging
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25031813 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Hwa Yeon Jeong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Laboratory Science, Yonsei University, Wonju 26493, Republic of Korea. Hauptthemen laut MEDLINE: Copper Radioisotopes, Doxorubicin, Liposomes, Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Ministry of Science and ICT, Nuclear Research & Development Program.
Abstract (Originalsprache)
Combining standard surgical procedures with personalized chemotherapy and the continuous monitoring of cancer progression is necessary for effective NSCLC treatment. In this study, we developed liposomal nanoparticles as theranostic agents capable of simultaneous therapy for and imaging of target cancer cells. Copper-64 (64Cu), with a clinically practical half-life (t1/2 = 12.7 h) and decay properties, was selected as the radioisotope for molecular PET imaging. An anti-epidermal growth factor receptor (anti-EGFR) antibody was used to achieve target-specific delivery. Simultaneously, the chemotherapeutic agent doxorubicin (Dox) was encapsulated within the liposomes using a pH-gradient method. The conjugates of 64Cu-labeled and anti-EGFR antibody-conjugated micelles were inserted into the doxorubicin-encapsulating liposomes via a post-insertion procedure (64Cu-Dox-immunoliposomes). We evaluated the size and zeta-potential of the liposomes and analyzed target-specific cell binding and cytotoxicity in EGFR-positive cell lines. Then, we analyzed the specific therapeutic effect and PET imaging of the 64Cu-Dox-immunoliposomes with the A549 xenograft mouse model. In vivo therapeutic experiments on the mouse models demonstrated that the doxorubicin-containing 64Cu-immunoliposomes effectively inhibited tumor growth. Moreover, the 64Cu-immunoliposomes provided superior in vivo PET images of the tumors compared to the untargeted liposomes. We suggest that nanoparticles will be the potential platform for cancer treatment as a widely applicable theranostic system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Laboratory Science, Yonsei University, Wonju 26493, Republic of Korea.
- Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea.
- Division of RI-Convergence Research, Korea Institute of Radiological and Medical Science, Seoul 01812, Republic of Korea.
ORCID-Profile: Min Woo Kim, Tae Sup Lee
Förderung
- Ministry of Education
- Ministry of Science and ICT
- Nuclear Research & Development Program
Zitieren
APA
Jeong, H. Y., Kang, S. J., Kim, M. W., Jeong, I. H., Choi, M. J., Jung, C., Song, I. H., Lee, T. S., & Park, Y. S. (2024). Development of PET Radioisotope Copper-64-Labeled Theranostic Immunoliposomes for EGFR Overexpressing Cancer-Targeted Therapy and Imaging. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25031813
Vancouver
Jeong HY, Kang SJ, Kim MW, Jeong IH, Choi MJ, Jung C, et al. Development of PET Radioisotope Copper-64-Labeled Theranostic Immunoliposomes for EGFR Overexpressing Cancer-Targeted Therapy and Imaging. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25031813
BibTeX
@article{Jeong2024,
author = {Jeong, Hwa Yeon and Kang, Seong Jae and Kim, Min Woo and Jeong, In-Ho and Choi, Moon Jung and Jung, Cheulhee and Song, In Ho and Lee, Tae Sup and Park, Yong Serk},
title = {Development of PET Radioisotope Copper-64-Labeled Theranostic Immunoliposomes for EGFR Overexpressing Cancer-Targeted Therapy and Imaging},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25031813}
}
EUVIMED